Previously we developed a carcinogenesis model involving the combination of 9,10dimethyl-1,2-benzanthracene (DMBA) application with physical wounding of hamster lingual mucosa. The presence of a novel hamster oral papillomavirus (HOPV) was demonstrated and its genome sequenced. In the present study, this HOPV hamster model was used to test whether vaccination with the L1 gene could prevent the development of oral carcinoma. DNA plasmids encoding the L1 gene or the vector alone were injected intramuscularly into 20 vaccinated and 20 control hamsters, respectively. The lingual tips of the hamsters were painted with DMBA for 8 weeks. A portion of the lingual tips was excised, and the tips were then painted daily with DMBA until the animals were killed 13 days later. All control hamsters developed lingual carcinoma, whereas 12 of the L1-vaccinated hamsters showed no lesions. These results suggest that immunization with L1 DNA vaccines may prevent the development of papillomavirus-associated oral cancer.
Introduction
We have previously developed a highly reproducible carcinogenesis model by combining 9,10-dimethyl-1,2-benzanthracene (DMBA) application with physical wounding of the hamster lingual mucosa. 1 Histologically, these lesions showed pathognomonic changes indicative of papillomavirus infection, including koilocytosis of dysplastic cells, and the nuclei of some of the dysplastic or cancerous cells were positive for papillomavirus genus-specific antigen. 2 Furthermore, viral particles resembling papillomavirus, 50 -55 nm in diameter, were detected in the nuclei of these cells. 3 Using the same animal model, we also demonstrated the presence of a novel hamster papillomavirus by molecular cloning and sequencing of the viral genome. 4 The genome was confirmed by complete sequence analysis to be a novel papillomavirus, and was designated the hamster oral papillomavirus (HOPV). Using in situ hybridization, we demonstrated the presence of HOPV in the nuclei of dysplastic and malignant lesions in hamster lingual epithelium. Computer-assisted phylogenetic analysis of HOPV showed differing homology from that of other papillomaviruses in various regions of the genome. The genome had open reading frames (ORFs) on one strand in the usual order: E6, E7, E1, E2, L2 and L1. ORF E2 contained the small ORF E4, but ORF E5 was missing. The cloned genome was different from those of other rodent papillomaviruses, such as Micromys minutus papillomavirus and Mastomys natalensis papillomavirus, and also from previously sequenced animal and human papillomavirus genomes.
Infection with HOPV seems to be a good model for investigating mucosal carcinogenesis associated with papillomavirus and also for the study of vaccine prophylaxis and the prevention or treatment of malignant conversion. In this study we used the HOPV hamster model to test whether vaccination with the L1 gene alone can prevent oral carcinoma development.
Materials and methods

ANIMALS
Male Syrian normally bred golden hamsters were obtained from SLC Co. Ltd (Hamamatsu, Japan). The hamsters were maintained under specific pathogen-free conditions. All experimental protocols were approved by the Institutional Animal Care and Use Committee of Aichi-Gakuin University, Nagoya, Japan.
PREPARATION OF PLASMID
An expression plasmid for HOPV L1 (pCMV-HOPV L1) was constructed from the expression vector pCMV-β (Clontech, Palo Alto, CA, USA), which contains the cytomegalovirus (CMV) promoter. After excision of the β-galactosidase ORF, a DNA fragment encoding the L1 protein, nucleotides 5604 -7151, amplified from cloned HOPV DNA, was added. The plasmid vector after the removal of the β-galactosidase gene (pCMV-0) was used as the control.
The plasmid DNA used for injection was purified using a QIAprep Spin Miniprep Kit (Qiagen, Valencia, California, USA). Shortly before injection, the DNA was precipitated and redissolved in saline at a concentration of 200 µg/100 µl.
DNA VACCINATION
The hamsters were divided equally into two groups. The control animals were injected intramuscularly into the rectus femoris with the vector pCMV-0 only, while those in the vaccinated group were injected with pCMV-HOPV L1 (200 µg in 100 µl saline). Three weeks after the initial DNA injection, all animals were boosted with the same plasmids they had received initially.
INDUCTION OF TUMOURS IN ANIMALS
Dysplastic lingual lesions were induced using a previously described protocol that had been reviewed and approved by the Animal Care and Use Committee. After DNA injection, the lingual tips of all animals were painted three times a week with a 0.5% solution of DMBA in acetone for 8 weeks. A portion of the lingual tip, 2 mm in longitudinal thickness, was then excised under anaesthesia. The tips were then painted daily with DMBA until the animals were killed 13 days later.
HISTOLOGICAL AND IMMUNOCYTOCHEMICAL EXAMINATION
The tongue tissues were fixed in 10% buffered formalin and embedded in paraffin. Paraffin sections were stained with haematoxylin and eosin for histological examination. A genusspecific papillomavirus antigen (GSPA) (Dako, Carpenteria, CA, USA) was used to confirm the presence of papillomavirus. All histological sections were stained using the 
IN SITU HYBRIDIZATION
DNA analysis was carried out on the formalin-fixed paraffin wax-embedded tissue using a DNA in situ hybridization technique with a PCR DIG Probe Synthesis Kit (Boehringer Mannheim, Mannheim, Germany) and the GenPoint™ System (Dako). Sections and probe DNA were denatured at 95°C, and hybridization was carried out overnight at 37°C under high stringency. After hybridization, slides were washed in stringent wash solution at 40°C. The sections were stained using the diaminobenzidine method, in which positive hybridization is indicated by brown intranuclear deposits.
Results
Forty hamsters, 3 weeks old with a body weight of 90 -95 g at the beginning of the experiment, were used for the study. All 20 hamsters in the control group, which were injected with the vector pCMV-0, developed lingual carcinoma (Table 1) . These carcinomas showed abnormal keratinization, disorientation of cells, cellular pleomorphism, nuclear hyperchromatism, nuclear atypia with koilocytosis, cytoplasmic inclusions and an increased number of mitotic figures (Fig. 1) . Immunocytochemically, all the animals in the control group also showed positive staining for GSPA in the nuclei of the superficial layer of the epithelium (Fig. 2) . HOPV DNA was detected on PCR amplification using primers for the L1 region and on in situ hybridization in all the control animals. HOPV DNA was also found in all control animals. With in situ hybridization, the positive signals aggregated into the nuclei throughout the epithelium of the control animals ( Fig. 3) .
Of the 20 animals injected with pCMV-HOPV L1, 12 showed no development of lingual carcinoma; HOPV DNA was not detected by PCR or in situ hybridization in these animals ( Table 1 ). The remaining eight animals developed lingual carcinomas similar to those of the control animals, and HOPV DNA was detected. oral carcinoma. In earlier studies using the CRPV model, injection of a DNA vaccine consisting of papillomavirus L1 resulted in the generation of antibodies against papillomavirus L1. 5, 6 These results, and ours, show that both CRPV and HOPV L1 genes can induce strong and specific humoral and cellular immune responses to L1, and prevent the development of animal papilloma or cancer. Furthermore, in the present study, 12 of 20 (60%) L1 DNAvaccinated hamsters were protected from oral carcinoma development, whereas all the control hamsters developed oral cancer. The results of this study suggest that immunization of humans with the expression plasmid for HPV L1 might protect them from infection with HPV and prevent cancer development in a type-specific manner.
DNA vaccines are capable of inducing both humoral and cell-mediated immune responses against viral proteins. 7 Naked DNA vaccines using plasmid DNA to induce cellular and humoral immunity represent an attractive approach for generating antigenspecific tumour immunotherapy, 8 although the mode and sequence of delivery of a DNA vaccine may influence the effectiveness of the immune responses produced. Intramuscular immunization is likely to target the antigen to myocytes; the antigen encoded by the DNA vaccine is eventually presented through bone marrow-derived antigen-presenting cells through the cross-priming mechanism. 9 It is therefore necessary to find an efficient route for administering DNA vaccines to the most appropriate target cells.
DNA vaccination based on the HPV L1 gene is a promising means towards the prevention of primary HPV infection, and may also be a useful component of a therapeutic approach. Vaccination against HPV to prevent infection and to treat premalignant disease could substantially H Maeda, K Kubo, Y Sugita et al. DNA vaccine against HOPV-associated oral cancer decrease the morbidity and mortality from cervical cancer. The ideal HPV vaccine would not only prevent the development of primary lesions but also provide therapy for established lesions.
Administration of L1-containing plasmid DNA via an intramuscular, oral or subcutaneous route has been shown to induce systemic and local antibodies. 10 The humoral immune responses induced by the DNA vaccine were shown to be able to inhibit virus-like particle (VLP)-mediated haemagglutination, but the cellular immune responses were not as strong as those observed in animal papillomavirus models. 9 Further research on improving the vaccine design to enhance its immune potential is currently in progress.
DNA vaccines have several advantages over other vaccines: 11 (i) They induce minimal anti-vector response, which allows the same vector to be used repeatedly; (ii) There is no antigenic competition between the vector and the target antigens; (iii) There is no risk of reversion to pathogenicity;
(iv) They can be prepared and purified easily; (v) They are stable at all temperatures, which allows economic transportation, especially in developing countries. In conclusion, the present study has shown that, in hamsters, considerable protection against HOPV-associated oral cancer development was produced by immunization with the HOPV L1 gene vaccine, suggesting that an L1 vaccine may prevent HOPVassociated cancer. Further studies will be needed to determine whether the HOPV L1 vaccine can also induce regression of already established lesions.
